Despite advances in tumour biology research, few tumour biomarker tests have been adopted as standard clinical practice. This lack of reliable biomarker tests stems from undervaluation, inconsistent regulatory standards and reimbursement, as well as insufficient investment in research and development, scrutiny of biomarker publications by journals, and evidence of analytical validity and clinical utility wrote USA researchers in a commentary published in the Science Translational Medicine. Read more here.
Article mentioned: Hayes DF, et al. Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31;5(196):196cm6. PMID: 23903752
No comments:
Post a Comment